Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Get Free Report) shares reached a new 52-week low during trading on Wednesday . The company traded as low as $17.70 and last traded at $17.75, with a volume of 81775 shares changing hands. The stock had previously closed at $19.19.
Wall Street Analyst Weigh In
A number of brokerages have recently weighed in on KYTX. Leerink Partnrs reiterated an "outperform" rating on shares of Kyverna Therapeutics in a research report on Monday, March 4th. Morgan Stanley began coverage on shares of Kyverna Therapeutics in a research report on Monday, March 4th. They issued an "overweight" rating and a $40.00 target price for the company. Wells Fargo & Company assumed coverage on shares of Kyverna Therapeutics in a research report on Monday, March 4th. They set an "overweight" rating and a $44.00 price target on the stock. SVB Leerink began coverage on Kyverna Therapeutics in a research report on Monday, March 4th. They set an "outperform" rating and a $48.00 price objective on the stock. Finally, JPMorgan Chase & Co. initiated coverage on Kyverna Therapeutics in a research report on Monday, March 4th. They issued an "overweight" rating and a $39.00 target price for the company. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has an average rating of "Buy" and an average price target of $42.75.
Check Out Our Latest Report on KYTX
Kyverna Therapeutics Trading Down 7.7 %
The company's 50 day moving average is $25.68.
Insider Buying and Selling at Kyverna Therapeutics
In related news, major shareholder Northpond Ventures Iii Gp, Llc bought 450,000 shares of the business's stock in a transaction dated Monday, February 12th. The shares were purchased at an average cost of $22.00 per share, with a total value of $9,900,000.00. Following the completion of the purchase, the insider now owns 450,000 shares in the company, valued at approximately $9,900,000. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website.
Kyverna Therapeutics Company Profile
(
Get Free Report)
Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Kyverna Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kyverna Therapeutics wasn't on the list.
While Kyverna Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
